No association between cyclooxygenase-2 and uridine diphosphate glucuronosyltransferase 1A6 genetic polymorphisms and colon cancer risk

World Journal of Gastroenterology

Volumn 15, Issue 18, 2009, Pages 2240-2244

  Thompson, Cheryl L ^a   Plummer, Sarah J ^b   Merkulova, Alona ^c   Cheng, Iona ^d   Tucker, Thomas C ^e   Casey, Graham ^b   Li, Li ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Colon cancer; Cyclooxygenase 2; Genetic association studies; Non steroidal anti inflammatory drugs; Single nucleotide polymorphisms; Uridine diphosphate glucuronosyltransferase 1A6

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2; GLUCURONOSYLTRANSFERASE 1A6; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; GLUCURONOSYLTRANSFERASE; UGT1A6 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER PREVENTION; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; DRUG USE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; SINGLE NUCLEOTIDE POLYMORPHISM; THERAPY EFFECT; AGED; COLON TUMOR; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; MIDDLE AGED; RISK FACTOR;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 67650179528     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.2240     Document Type: Article

References (17)

1. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183-1188
2. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999; 18: 7908-7916
3. Bosetti C, Gallus S, La Vecchia C. Aspirin and cancer risk: an updated quantitative review to 2005. Cancer Causes Control 2006; 17: 871-888
4. Goodman JE, Bowman ED, Chanock SJ, Alberg AJ, Harris CC. Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk. Carcinogenesis 2004; 25: 2467-2472
5. Siezen CL, Bueno-de-Mesquita HB, Peeters PH, Kram NR, van Doeselaar M, van Kranen HJ. Polymorphisms in the genes involved in the arachidonic acid-pathway, fish consumption and the risk of colorectal cancer. Int J Cancer 2006; 119: 297-303
6. Ulrich CM, Whitton J, Yu JH, Sibert J, Sparks R, Potter JD, Bigler J. PTGS2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev 2005; 14: 616-619
7. Cox DG, Pontes C, Guino E, Navarro M, Osorio A, Canzian F, Moreno V. Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/ COX2) and risk of colorectal cancer. Br J Cancer 2004; 91: 339-343
8. Wiesner GL, Platzer P, Buxbaum S, Lewis S, MacMillen M, Olechnowicz J, Willis J, Chakravarti A, Elston RC, Markowitz SD. Testing for colon neoplasia susceptibility variants at the human COX2 locus. J Natl Cancer Inst 2001; 93: 635-639
9. Ciotti M, Marrone A, Potter C, Owens IS. Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications. Pharmacogenetics 1997; 7: 485-495
10. Bigler J, Whitton J, Lampe JW, Fosdick L, Bostick RM, Potter JD. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. Cancer Res 2001; 61: 3566-3569
11. Chan AT, Tranah GJ, Giovannucci EL, Hunter DJ, Fuchs CS. Genetic variants in the UGT1A6 enzyme, aspirin use, and the risk of colorectal adenoma. J Natl Cancer Inst 2005; 97: 457-460
12. McGreavey LE, Turner F, Smith G, Boylan K, Timothy Bishop D, Forman D, Roland Wolf C, Barrett JH. No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARdelta and PPARgamma act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma. Pharmacogenet Genomics 2005; 15: 713-721
13. Samowitz WS, Wolff RK, Curtin K, Sweeney C, Ma KN, Andersen K, Levin TR, Slattery ML. Interactions between CYP2C9 and UGT1A6 polymorphisms and nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Clin Gastroenterol Hepatol 2006; 4: 894-901
14. Hubner RA, Muir KR, Liu JF, Logan RF, Grainge M, Armitage N, Shepherd V, Popat S, Houlston RS. Genetic variants of UGT1A6 influence risk of colorectal adenoma recurrence. Clin Cancer Res 2006; 12: 6585-6589
15. Li L, Plummer SJ, Thompson CL, Tucker TC, Casey G. Association between phosphatidylinositol 3-kinase regulatory subunit p85alpha Met326Ile genetic polymorphism and colon cancer risk. Clin Cancer Res 2008; 14: 633-637
16. Shahedi K, Lindström S, Zheng SL, Wiklund F, Adolfsson J, Sun J, Augustsson-Bälter K, Chang BL, Adami HO, Liu W, Grönberg H, Xu J. Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int J Cancer 2006; 119: 668-672
17. Potter JD. Colorectal cancer: molecules and populations. J Natl Cancer Inst 1999; 91: 916-932